Cell and Gene Therapy in Canada - Insights Magazine

As industry trends continue to point toward increased consolidator interest, the Canadian cell and gene sector is advancing technology and moving towards commercialization. Back Bay Life Science Advisors shares which Canadian companies are progressing technology in the sector and offers a perspective of the inherent nuances of Canada’s unique market dynamics and public health insurance system.

Canadian biotechs are producing novel cell and gene therapy innovations; in this article, we highlight several that we find particularly compelling

Cell and Gene Therapy in Canada: Leading Companies and the Commercial Opportunity” in now available in Insights Magazine via BIOTECanada.

Back Bay Life Science Advisors has a special and nuanced understanding of the scientific, clinical and commercial positioning of novel cell and gene therapy technologies. We're thrilled the special BIO edition of Insights Magazine features an article by Kyle O'Neil and Brendan Wang of Back Bay Life Science Advisors about the continuation of increased consolidator interest in the Canadian cell and gene sector.

Pick up a copy of Insights Magazine at this year's BIO 2022 conference in San Francisco or read it here, or download the pdf by clicking on the image below. The article begins on page 16.